T-Cell and NK-Cell Infiltration into Solid Tumors: A Key Limiting Factor for Efficacious Cancer Immunotherapy

Cancer Discovery (Impact Factor: 19.45). 05/2014; 4(5):522-6. DOI: 10.1158/2159-8290.CD-13-0985
Source: PubMed


Cancer immunotherapy has great promise, but is limited by diverse mechanisms used by tumors to prevent sustained antitumor immune responses. Tumors disrupt antigen presentation, T/NK-cell activation, and T/NK-cell homing through soluble and cell-surface mediators, the vasculature, and immunosuppressive cells such as myeloid-derived suppressor cells and regulatory T cells. However, many molecular mechanisms preventing the efficacy of antitumor immunity have been identified and can be disrupted by combination immunotherapy. Here, we examine immunosuppressive mechanisms exploited by tumors and provide insights into the therapies under development to overcome them, focusing on lymphocyte traffic. Cancer Discov; 4(5); 522-6. ©2014 AACR.

36 Reads
  • [Show abstract] [Hide abstract]
    ABSTRACT: Epithelial ovarian cancer (EOC) is one of the most mortal carcinomas in females. Immune systems can recognize EOCs; however, a defect of HLA class I ex-pression is known to be a major mechanism for escape from immune systems, resulting in poor prognosis. The purpose of this study is to find novel relations between immunological response and other clinical factors. We investigated expression of immunological components in 122 cases of EOC for which opera-tions were performed in the period from 2001 to 2011. We stained EOC specimens immunohistochemically using an anti-pan HLA class I monoclonal antibody (EMR 8-5) and CD3, CD4, CD8 antibodies, and we analyzed correla-tions with immunological parameters and clinical factors. In multivariate analy-sis used the Cox proportional hazards model, independent prognostic factors for overall survival in advanced EOC were low expression level of HLA class I (RR= 1.97, 95%CI=1.01-3.83; p=0.046) and loss of intraepithelial cytotoxic T lympho-cyte (CTL) infiltration (RR=2.11, 95%CI=1.06-4.20; p=0.033). Interestingly, almost all platinum-resistant cases showed a significantly low rate of intraepi-thelial CTL infiltration in the χ square test (positive vs negative: 9.0% vs 97.7%, p<0.001). A logistic regression model revealed that low CTL infiltration rate was an independent factor of platinum resistance in multivariate analysis (OR=3.77, 95%CI=1.08-13.12; p=0.037). Platinum-resistant EOC shows poor immunological responses. The immune escape system of EOC may be one of the mechanisms of platinum resistance.
    10/2014; 2(12). DOI:10.1158/2326-6066.CIR-14-0101
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Cancer immunotherapy has recently emerged as an important treatment modality. FDA approval of provenge, ipilimumab and pembrolizumab has started to deliver on the long awaited promise of cancer immunotherapy. Many new modalities of immunotherapies targeting cytotoxic T lymphocytes (CTLs) responses, such as adoptive cell therapies and vaccines, are in advanced clinical trials. In all these immunotherapies, migration of CTLs to the tumor site is a critical step for achieving therapeutic efficacy. However, inefficient infiltration of activated CTLs into established tumors is increasingly being recognized as one of the major hurdles limiting efficacy. Mechanisms that control migration of CTLs to tumors are poorly defined. In this review, the authors discuss the chemoattractants and their receptors that have been implicated in endogenous- or immunotherapy-induced CTL recruitment to tumors and the potential for targeting these pathways for therapeutic efficacy.
    Expert Review of Vaccines 12/2014; 14(4):1-13. DOI:10.1586/14760584.2015.982101 · 4.21 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Vaccine-based cancer immunotherapy has generated highly variable clinical results due to differing methods of vaccine preparation and variation in patient populations among other lesser factors. Moreover, these clinical responses do not necessarily correspond with the induction of tumor-specific cytotoxic lymphocytes. Here, we review the participation of natural killer (NK) cells as alternative immune components that could cooperate in successful vaccination treatment. NK cells have been described as helper cells in dendritic cell-based cancer vaccines, but the role in other kinds of vaccination strategies (whole cells, peptide, or DNA-based vaccines) is poorly understood. In this article, we address the following issues regarding the role of NK cells in cancer vaccines: NK cell anti-tumor action sites, and the loci of NK cell interaction with other immune cells; descriptions of new data on the memory characteristics of NK cells described in infectious diseases; and finally phenotypical and functional changes after vaccination measured by immunomonitoring in preclinical and clinical settings.
    Frontiers in Immunology 01/2015; 6:13. DOI:10.3389/fimmu.2015.00013
Show more